Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy

William L Hwang; Andrzej Niemierko; Katie L Hwang; Harper Hubbeling; Emily Schapira; Justin F Gainor; Florence K Keane

doi:10.1001/jamaoncol.2017.3808

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy

JAMA Oncol. 2018 Feb 1;4(2):253-255. doi: 10.1001/jamaoncol.2017.3808.

Authors

William L Hwang^{1

2}, Andrzej Niemierko², Katie L Hwang^{2

3}, Harper Hubbeling^{3

4}, Emily Schapira^{2

3}, Justin F Gainor⁴, Florence K Keane²

Affiliations

¹ Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts.
² Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Abstract

This cohort study evaluates the clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy.

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / immunology*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / epidemiology
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / radiotherapy*
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / epidemiology
Lung Neoplasms / pathology
Lung Neoplasms / radiotherapy*
Male
Middle Aged
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology*
Protein-Tyrosine Kinases / therapeutic use
Radiotherapy, Adjuvant
Radiotherapy, Conformal
Retrospective Studies
Thorax
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Protein-Tyrosine Kinases